Ep. 147: “Targeted Repair in Blood Stem and Progenitor Cells” Featuring Dr. Jennifer Adair

Guest: Dr. Jennifer Adair is an Assistant Member in the Clinical Research Division at Fred Hutchinson Cancer Research Center. Her lab uses a combination of cell biology, molecular biology, chemistry, engineering, nanomedicine and bioinformatics to develop new gene therapy treatments for many different diseases, including cancer. Her goal is to develop safe, cost-effective and clinically relevant applications for gene therapy that can be implemented worldwide. Featured Products and Resources: Science in Seattle StemSpan SFEM II Resources and Links Possible Drug Target for Heart Condition Identified - Researchers have found that a genetic mutation linked to dilated cardiomyopathy activates a signaling pathway that is normally turned off in healthy adult hearts. Fibrosis Target Identified - Investigators have identified a protease that is activated by TGFβ that contributes to fibrosis development. Improved Kidney Organoids - Scientists have developed a protocol for generating vascularized and functional human PSC-derived 3D kidney organoids, and used them to model disease. New Tool for Immune Monitoring using Mass Cytometry - A mass cytometry workflow has been developed for identifying major immune cell lineages to improve biomarker discovery in immunotherapy trials. Delayed Neurodevelopment in Zika-Exposed Children - In this prospective cohort study, the authors found that one third of children up to age three who were exposed to Zika in-utero had below-average neurological development. Photo Reference: Courtesy of Dr. Jennifer Adair Subscribe to our newsletter! Never miss updates about new episodes. Subscribe